Business Wire·Nov 10, 2026, 1:00 AM ET

Genentech and Roche Present New Data Across Pharmaceuticals and Diagnostics From Its Growing Alzheimer’s Disease Portfolio at CTAD 2026

RHHBY

Genentech & Roche will present 16 accepted abstracts at the 19th CTAD Congress in Boston from November 16-19, 2026, to highlight a strategy uniting diagnostic testing with targeted therapeutics.
The Phase II TARBELA-AD study has commenced to evaluate the oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease, targeting neuroinflammation.
Updated Phase Ib/IIa Brainshuttle™ AD study data for trontinemab will demonstrate rapid amyloid removal dynamics & changes in key biomarkers.
The Phase III PrevenTRON study design for trontinemab in preclinical Alzheimer's disease has been announced, with enrollment recently started.
Global clinical & health economic data will be presented for the Elecsys® pTau217 & Elecsys pTau181 blood tests to support accessible diagnosis.
Scientific symposia will cover trontinemab neuroimaging insights on November 16 & NLRP3 inflammasome targeting data on November 17.
A keynote address by Geoff Kerchner will explore the evolution of diagnostics, therapies, trials, & prevention concepts on November 17.
An oral presentation on November 18 will detail the PrevenTRON study design & participant screening for cognitively unimpaired individuals at high risk.
Multiple poster sessions will display data on pTau blood test validation, economic evaluations, & real-world utilization across diverse global populations.
Genentech & Roche continue to advance a multi-mechanism pipeline including trontinemab, nivegacetor, RG6434, & Brainshuttle™ technology for blood-brain barrier transport.